Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

30 mars 2015 uppdaterad av: Sanofi

Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy

Primary Objective:

To demonstrate progression free survival (PFS) improvement for cabazitaxel compared to topotecan in participants with sensitive or resistant/refractory small cell lung cancer following a first line platinum based chemotherapy.

Secondary Objectives:

  • To assess disease progression free rate at 12 weeks
  • To assess Response Rate (Response Evaluation Criteria in Solid Tumor [RECIST] 1.1) and duration of response
  • To assess Overall Survival (OS)
  • To assess the Safety (National Cancer Institute - Common Toxicity Criteria [NCI-CTC] version 4.03)
  • To assess the Health-Related Quality of Life (HRQoL)

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Participants are to be treated until progressive disease, unacceptable toxicity or refusal for further study treatment.

All participants are to be followed for disease progression documentation and for participant status until the study cut-off date.

Studietyp

Interventionell

Inskrivning (Faktisk)

179

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Brasilien
      • Porto Alegre, Brasilien, 90610-000
        • Investigational Site Number 076001
  • Chile
      • Santiago, Chile, 8380456
        • Investigational Site Number 152001
      • Santiago, Chile
        • Investigational Site Number 152005
  • Frankrike
      • Brest, Frankrike, 29609
        • Investigational Site Number 250005
      • Caen Cedex, Frankrike, 14033
        • Investigational Site Number 250004
      • La Tronche, Frankrike, 38700
        • Investigational Site Number 250006
      • Lille, Frankrike, 59800
        • Investigational Site Number 250002
      • Saint-Herblain Cedex, Frankrike, 44805
        • Investigational Site Number 250003
      • Villejuif Cedex, Frankrike, 94805
        • Investigational Site Number 250007
  • Förenta staterna
    • Alabama
      • Muscle Shoals, Alabama, Förenta staterna, 35661
        • Investigational Site Number 840007
    • Nebraska
      • Omaha, Nebraska, Förenta staterna, 68114
        • Investigational Site Number 840005
    • New Hampshire
      • Lebanon, New Hampshire, Förenta staterna, 03756
        • Investigational Site Number 840006
    • Ohio
      • Middletown, Ohio, Förenta staterna, 45042
        • Investigational Site Number 840003
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Investigational Site Number 840001
  • Grekland
      • Athens, Grekland, 11522
        • Investigational Site Number 300005
      • Athens, Grekland, 11527
        • Investigational Site Number 300003
      • Heraklion, Grekland, 71110
        • Investigational Site Number 300001
      • Thessaloniki, Grekland, 54629
        • Investigational Site Number 300002
      • Thessaloniki, Grekland, 57010
        • Investigational Site Number 300004
  • Italien
      • Genova, Italien, 16132
        • Investigational Site Number 380001
      • Livorno, Italien, 57123
        • Investigational Site Number 380002
      • Novara, Italien, 28100
        • Investigational Site Number 380005
      • Parma, Italien, 43100
        • Investigational Site Number 380004
  • Kanada
      • Montreal, Kanada, H3T 1E2
        • Investigational Site Number 124003
      • Oshawa, Kanada, L1G 2B9
        • Investigational Site Number 124002
      • Rimouski, Kanada, G5L 5T1
        • Investigational Site Number 124004
      • Toronto, Kanada, M5G 2M9
        • Investigational Site Number 124001
  • Korea, Republiken av
      • Seoul, Korea, Republiken av, 120-752
        • Investigational Site Number 410001
      • Seoul, Korea, Republiken av, 135-710
        • Investigational Site Number 410003
      • Seoul, Korea, Republiken av, 138-736
        • Investigational Site Number 410002
  • Norge
      • Oslo, Norge, 0440
        • Investigational Site Number 578001
      • Stavanger, Norge, 4011
        • Investigational Site Number 578003
      • Trondheim, Norge, 7006
        • Investigational Site Number 578002
  • Polen
      • Gdansk, Polen, 80-952
        • Investigational Site Number 616004
      • Lublin, Polen, 20-954
        • Investigational Site Number 616003
      • Poznan, Polen, 60-569
        • Investigational Site Number 616002
      • Warszawa, Polen, 02-781
        • Investigational Site Number 616001
  • Rumänien
      • Cluj Napoca, Rumänien, 400015
        • Investigational Site Number 642003
      • Cluj-Napoca, Rumänien, 400015
        • Investigational Site Number 642005
      • Craiova, Rumänien, 200385
        • Investigational Site Number 642001
      • Timisoara, Rumänien
        • Investigational Site Number 642002
  • Ryska Federationen
      • Moscow, Ryska Federationen, 115478
        • Investigational Site Number 643001
      • St-Petersburg, Ryska Federationen, 197758
        • Investigational Site Number 643005
      • Tula, Ryska Federationen, 300053
        • Investigational Site Number 643006
      • Yaroslavl, Ryska Federationen, 150054
        • Investigational Site Number 643003
  • Spanien
      • Badalona, Spanien, 08916
        • Investigational Site Number 724002
      • Barcelona, Spanien, 08035
        • Investigational Site Number 724004
      • Málaga, Spanien, 29010
        • Investigational Site Number 724005
      • Valencia, Spanien, 46026
        • Investigational Site Number 724001
  • Tyskland
      • Großhansdorf, Tyskland, 22927
        • Investigational Site Number 276003
      • Löwenstein, Tyskland, 74245
        • Investigational Site Number 276006
  • Ukraina
      • Dnipropetrovsk, Ukraina, 49102
        • Investigational Site Number 804002
      • Donetsk, Ukraina, 83092
        • Investigational Site Number 804004
      • Lviv, Ukraina, 70031
        • Investigational Site Number 804001
  • Ungern
      • Budapest, Ungern, 1121
        • Investigational Site Number 348001
      • Budapest, Ungern, 1121
        • Investigational Site Number 348004
      • Budapest, Ungern, 1125
        • Investigational Site Number 348002
      • Törökbálint, Ungern, 2045
        • Investigational Site Number 348003

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion criteria :

  • Histological/cytological proven locally advanced or metastatic small cell lung cancer with progressive disease during or after first line platinum based chemotherapy
  • Male or female greater than or equal to (>=) 18 years (or country's legal age of majority if greater than [>]18 years)
  • Participants with measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1)
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (<=) 1

Exclusion criteria:

  • Absence of signed and dated Institutional Review Board (IRB)-approved participant informed consent form prior to enrollment into the study
  • More than one prior chemotherapy regimen. Prior treatment with topotecan or taxanes
  • Less than 28 days elapsed from prior treatment with chemotherapy, radiotherapy or surgery to the time of randomization (Radiotherapy for bone pain palliation is allowed)
  • Adverse events (excluding alopecia) from any prior anticancer therapy of grade >1 (National Cancer Institute Common Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization
  • Uncontrolled Central Nervous System (CNS) metastases: participants with CNS metastases may have previous irradiation, only participants with stable disease or response to irradiation who are without CNS symptoms and on a maximum steroid dose of dexamethasone 8 mg daily or equivalent could be included
  • Participants with known leptomeningeal metastases
  • History of other, invasive neoplasm requiring ongoing therapy
  • Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization
  • Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association class III or IV congestive heart failure, stroke or transient ischemic attack
  • Any severe acute or chronic medical condition, which could impair the ability of the participant to participate in the study or interfere with interpretation of study results
  • Known Human Immunodeficiency Virus (HIV) disease, or active hepatitis B or C (systematic testing was not required)
  • Pregnant or breast-feeding woman. Positive serum or urine pregnancy test prior to randomization
  • Participant with reproductive potential (M/F) who did not agree to use an accepted and effective method of contraception during the study treatment period and for at least 6 months after the completion of the study treatment. The definition of "effective method of contraception" was based on the investigator's judgment. Effective method of contraception should also be adapted to local regulation
  • History of hypersensitivity to polysorbate 80

  • Inadequate organ and bone marrow function as evidenced by:

    • Hemoglobin less than [<] 9.0 gram per deciliter (g/dL)
    • Absolute neutrophil count <1.5 x 10^9 per liter
    • Platelet count <100 x 10^9 per liter
    • Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and/or alanine aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) >2.5 x Upper Limit of Normal (ULN)
    • Alkaline Phosphatase (AP) >2.5 x ULN. In case of liver metastases AP >5 x ULN
    • Total bilirubin >1.0 x ULN
    • Serum Creatinine >1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to Chronic Kidney Disease Epidemiology Collaboration formula, and creatinine clearance <60 milliliter per minute (mL/min) was exclude the participant.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Cabazitaxel
Läkemedel: Cabazitaxel
Cabazitaxel 25 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
Andra namn:
  • XRP6258
Aktiv komparator: Topotecan
Läkemedel: Topotecan
Topotecan 1.5 mg/m^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression Free Survival (PFS)
Tidsram: Randomization to first tumor progression/clinical deterioration or death (maximum 7.6 months)
PFS was defined as the time interval from the date of randomization to the date of occurrence of the first documented tumor progression or death due to any cause, whichever came first. Median PFS was estimated using the Kaplan-Meier method. Progression was defined using Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study or unequivocal progression of existing non-target lesion. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.
Randomization to first tumor progression/clinical deterioration or death (maximum 7.6 months)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall Survival
Tidsram: From randomization to date of death (maximum 15 months)
Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was to be censored at the last date the participant was known to be alive. Median time was estimated by Kaplan-Meier curve.
From randomization to date of death (maximum 15 months)
Progression Free Rate at Week 12
Tidsram: Week 12
Progression was defined using Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study or unequivocal progression of existing non-target lesion. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Death due to disease progression within 12 weeks without radiological documentation of progressive disease was counted as an event. Percentage of participants who were progression free at week 12 are reported.
Week 12
Overall Objective Tumor Response Rate
Tidsram: Randomization to disease progression/occurrence (maximum 7.6 months)
Overall objective tumor response was defined as the proportion of participants with confirmed RECIST 1.1 achieving a complete response (CR) or partial response (PR). CR was defined as disappearance of all target/non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants with overall objective tumor response is reported.
Randomization to disease progression/occurrence (maximum 7.6 months)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Sanofi

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 mars 2012

Primärt slutförande (Faktisk)

1 april 2014

Avslutad studie (Faktisk)

1 april 2014

Studieregistreringsdatum

Först inskickad

22 december 2011

Först inskickad som uppfyllde QC-kriterierna

27 december 2011

Första postat (Uppskatta)

28 december 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

13 april 2015

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 mars 2015

Senast verifierad

1 mars 2015

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • ARD12166
  • 2011-003415-31 (EudraCT-nummer)
  • U1111-1123-3503 (Annan identifierare: UTN)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera